We then aimed to investigate whether pharmacologic inhibition of PI3K/AKT signaling node using clinically validated drug also recapitulates the antitumor and immunomodulatory benefits of Uro A or not, we next examined the effects of Omipalisib (PI3Ki, GSK2126458), a clinically approved potent inhibitor of PI3K/mTOR signaling pathway, on tumor growth and immunomodulation in vivo. This evidence concerns the gene AKT1 and neoplasm.